| Original language | English (US) |
|---|---|
| Pages (from-to) | 643-650 |
| Number of pages | 8 |
| Journal | The Lancet Neurology |
| Volume | 11 |
| Issue number | 7 |
| DOIs |
|
| State | Published - Jul 2012 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet Neurology, Vol. 11, No. 7, 07.2012, p. 643-650.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Sham neurosurgical procedures in clinical trials for neurodegenerative diseases
T2 - Scientific and ethical considerations
AU - Galpern, Wendy R.
AU - Corrigan-Curay, Jacqueline
AU - Lang, Anthony E.
AU - Kahn, Jeffrey
AU - Tagle, Danilo
AU - Barker, Roger A.
AU - Freeman, Thomas B.
AU - Goetz, Christopher G.
AU - Kieburtz, Karl
AU - Kim, Scott Y.H.
AU - Piantadosi, Steven
AU - Comstock Rick, Amy
AU - Federoff, Howard J.
N1 - Funding Information: The National Institutes of Health (NIH) convened a meeting of international experts to discuss the complex issues surrounding the decision to include sham neurosurgical procedures in clinical trials at a workshop entitled Sham Neurological Procedures in Clinical Trials for Neurodegenerative Diseases: Scientific and Ethical Considerations (June 30–July 1, 2010). The deliberations at this meeting were used in the development of this manuscript, and the authors acknowledge the contributions of the meeting participants. Authors were selected by the Organising Committee (WRG, JC-C, AEL, DT, and HJF) to represent the areas of expertise and opinions represented at the meeting. Authors include the members of the Organising Committee and a subset of meeting participants with expertise in clinical trials, neurology, neurosurgery, basic science research, ethics, and patient advocacy. A participant roster, slide presentations, written public comments, and a webcast are available online . The meeting was funded by the NIH . We also thank the following staff from the Office of Biotechnology Activities, NIH, for their contributions in bringing together this symposium: R Jambou, E Rosenthal, M O'Reilly, M Montgomery, and L Gargiulo. We also thank Perry Cohen for his contributions in the development of this symposium. The points described should not be interpreted to represent a consensus statement or the opinions of any individual or the NIH.
PY - 2012/7
Y1 - 2012/7
UR - http://www.scopus.com/inward/record.url?scp=84862311445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862311445&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(12)70064-9
DO - 10.1016/S1474-4422(12)70064-9
M3 - Comment/debate
C2 - 22710757
AN - SCOPUS:84862311445
SN - 1474-4422
VL - 11
SP - 643
EP - 650
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 7
ER -